Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

Click here to see some testimonials from our members!

Johnson & Johnson Shares Strong Since Actelion Acquisition, But Potential For Upside Remains

Courtesy of Benzinga.

Johnson & Johnson Shares Strong Since Actelion Acquisition, But Potential For Upside Remains

Johnson & Johnson (NYSE: JNJ) shares are up about 20 percent since the company acquired Actelion back in January. However, despite the strong performance, Credit Suisse analyst Vamil Divan sees more upside ahead for the pharma giant.

On Thursday, Credit Suisse reinstated coverage of Johnson & Johnson stock with an Outperform rating and $148 price target. According to Divan, Johnson & Johnson has several key growth drivers ahead.

tipranks.png

“Based on channel checks and detailed modeling we have done across various therapeutic areas, we see opportunities for significant upside from assets such as Xarelto, Darzalex and Imbruvica,” Divan wrote.

Related Link: Attention To Details: Neos’ ADHD Portfolio

He noted that these growth drivers are not necessarily a result of the Actelion buyout. In fact, Divan said that at $29.1 billion, Johnson & Johnson likely overpaid for Actelion. Still, the deal certainly adds another long-term growth avenue for Johnson & Johnson.

In the near term, Johnson & Johnson has two potentially bullish catalysts ahead.

First, the company is expected to release COMPASS data for Xarelto at the European Society of Cardiology conference on August 29. Shortly thereafter, Johnson & Johnson has the PDUFA date for sirukumab in mod-sensitive rheumatoid arthritis on Sept. 22.

In addition, investors should look for the addition of more Remicade biosimilars in the second half of 2017, Divan said.

Over the long term, Divan sees the pharma business as the major growth driver. Credit Suisse estimates 5.8 percent compound annual growth from the pharma business through 2021 compared to just 3.7 percent annual growth for the medical devices business and 3.1 percent annual growth from the consumer business.

Credit Suisse’s $148 price target is based on 18.5x the company’s 2018 EPS forecast of $7.79.

__________

Image Credit: By Raysonho @ Open Grid Scheduler / Grid Engine – Own work, CC0, via Wikimedia Commons

Latest Ratings for JNJ

Date Firm Action From To
Jul 2017 Credit Suisse Reinstates Outperform
May 2017 JP Morgan Upgrades Neutral Overweight
Jan 2017 Wells Fargo Downgrades Outperform Market Perform

View More Analyst Ratings for JNJ


View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas Price Target Initiation M&A Analyst Ratings Trading Ideas Best of Benzinga


Do you know someone who would benefit from this information? We can send your friend a strictly confidential, one-time email telling them about this information. Your privacy and your friend's privacy is your business... no spam! Click here and tell a friend!





You must be logged in to make a comment.
You can sign up for a membership or get a FREE Daily News membership or log in

Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

Click here to see some testimonials from our members!